搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
4 天
Stifel维持Blueprint Medicines买入评级,目标价155美元
周四,Stifel重申了对Blueprint Medicines (NASDAQ:BPMC)股票的买入评级,目标价为155.00美元。该公司的评论强调了Blueprint Medicines在过敏和炎症市场的进展,特别是其主打产品Ayvakit的商业成功。
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
今日热点
Left note, bail denied
Daylight saving time
Didn't authorize apology
1951 kidnap victim found
Visits US ammunition plant
Robinson loses key staff
Free COVID-19 tests
NE electoral change blocked
San Francisco homelessness
Economic speech this week
Donlon's homes searched
Astronauts return to Earth
SpaceX plans Mars missions
California plastic bag ban
No. 1 at box office again
Iran coal mine blast
Bulls escape MA rodeo
To meet Vietnamese pres
PM Modi visits US
Co-founder testifies
Dolphins legend Morris dies
Gulf Coast storm warning
FBI: Violent crime declined
No govt. shutdown for now
Tech ban proposed
Former WA governor dies
More troops to Middle East
Makes emergency landing
反馈